ASCO: AstraZeneca's oral SERD tied to 56% PFS benefit in phase 3 breast cancer trial
AstraZeneca has produced data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival in a phase 3 breast cancer study.
AstraZeneca has produced data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival in a phase 3 breast cancer study.
